Author

Shi-Qing Zhao

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

T-cell dysregulation in systemic lupus erythematosus: a four-layered model from extracellular cues to epigenetic remodeling and therapeutic opportunities.

Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disease in which the breakdown of T-cell tolerance is increasingly recognized as a central and therapeutically tractable event. Herein, we synthesize the spectrum of T-cell abnormalities in SLE and elucidate the underlying molecular mechanism...

Xiao-Yi Zheng, Hong-Rui Liu, Yong-Kang Chen et al. · Autoimmunity Reviews · 0 citations

Review Open access Oct 2026

Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis

This study aimed to synthesize evidence from recent randomized controlled trials (RCTs) evaluating the efficacy of regorafenib, fruquintinib, and TAS-102 in patients with metastatic colorectal cancer (mCRC). Using a network meta-analysis, we compared long-term survival outcomes (overall and progression-free surviva...

Ying-Yu Zhou, Shi-Qing Zhao, Xiao-Yi Zheng et al. · Frontiers in Oncology · 0 citations

Open access Sep 2026

A PBPK-VBE approach for bioequivalence extrapolation of senaparib capsule strengths in the context of nonlinear pharmacokinetics: bridging from the clinical starting dose to the linear pharmacokinetic range

Aims Senaparib (Sepalna®), a novel oral poly (adenosine diphosphate -ribose) polymerase (PARP) 1/2 inhibitor, was approved in China in 2025 as maintenance therapy for advanced ovarian cancer. The recommended starting dose is 100 mg once daily, which may be adjusted to 80 mg, 60 mg, or 40 mg to manage adverse events. Wh...

Xiao-Fei Wu, Zi-Yang Wang, Yan-Na He et al. · Frontiers in Pharmacology · 0 citations